Latest Revenue Growth News

NTAW Holdings improved margins, reduced inventory and cut gross debt in FY2026, but remained loss-making as revenue fell sharply after the loss of key distribution rights. Management is targeting modest growth in FY2027 while covenant obligations and cash generation remain central tests.

Emyria’s FY26 annual report shows a rapidly expanding psychedelic-assisted care network, with revenue up 210% and treatment capacity reaching 18 beds across four states. The gains came alongside a larger loss, $4.6 million in operating cash outflow and an auditor-highlighted material uncertainty over the company’s ability to continue without further funding.

Simonds Group delivered a sharp FY26 earnings rebound, with NPAT rising 950% to $10.5 million as revenue, site starts and margins all improved. The annual report also flags a qualified sustainability reporting outcome and a new Western Australian venture that will require execution and cash.

Inghams Group Limited (ASX:ING) returned to poultry volume growth in FY26, but rising costs, a tax dispute and weaker earnings sharply reduced shareholder returns. The company enters FY27 with lower net debt, elevated leverage and a value-led turnaround strategy still to prove itself.

Medical Developments International returned to EBIT profitability in FY26 as Penthrox volumes strengthened across Australian hospitals and Europe. The company now faces the less glamorous test of converting regulatory progress into repeatable demand while absorbing weaker Respiratory sales and new amortisation costs.

Orcoda has expanded workforce volumes under its Wagner and Wellcamp agreement, generating approximately $2.35 million in revenue during the September quarter. The facility is now being scaled towards its current capacity of 1,000 workers per day.

Trajan Scientific and Medical (ASX:TRJ) says FY27 has begun with improving revenue, quarterly nEBITDA of about A$3.5 million and a A$1.6 million reduction in net debt. The company expects mid-single-digit organic revenue growth and double-digit nEBITDA growth for the year, although its latest quarterly figures remain unaudited.

hipages Group delivered stronger FY26 cash generation, expanded into insurance and set higher targets for revenue, margins and free cash flow in FY27. The headline profit surge was substantially helped by an $8.9 million deferred tax benefit, making cash flow and platform adoption the more useful measures of progress.

Savana US Small Caps Active ETF (ASX:SVNP) fell 7.65% in September, trailing the S&P SmallCap 600 by 4.92 percentage points as higher US bond yields and a concentrated AI rally split the market. The manager says its valuation discipline kept it away from the month’s strongest semiconductor performers, while highlighting a 52% gain from its Everforth investment.

Eden Innovations reported a sharp acceleration in US sales during Q1 FY27, led by a 247% jump in OptiBlend revenue and expanding EdenCrete plant installations. The figures are unaudited management results, but they give the company a stronger opening quarter for the new financial year.

ReNerve’s October AGM presentation points to sharply higher sales, a growing US distribution network and a broader nerve repair pipeline. The company is also progressing a 240-patient NervAlign clinical study while relying on a $5 million RiverFort funding facility to support expansion.

IODM has secured the first 15 university commitments in its planned 283-university US rollout, while revenue rose 10.2% despite a sharp fall in UK international student visa applications. The onboarding is not yet revenue, but the December-quarter target gives investors a clear execution test.